Q3 2020
Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001493152-20-020593
Q3 2020 · 10-Q
Revenue$2.12M$2.12M −31.5% vs Q3 2019+34.5% vs Q2 2020
Net Income-$1.01M-$1.01M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.12-$0.12 N/M vs Q3 2019N/M vs Q2 2020
Gross Profit$1,225,000−32.7%
Operating Income-$932,000N/M
Operating Cash Flowderived-$1,817,000N/M
Free Cash Flowderived-$1,830,000—
Margins · derived
Gross margin57.8%−1.0 pt vs Q3 2019
Operating margin-43.9%−21.5 pt vs Q3 2019
Net margin-47.7%−23.7 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $2.12M | $3.10M | $1.72M | $916.00K |
| Net Income | -$1.01M | -$744.00K | -$566.00K | -$632.00K |
| EPS Diluted | -$0.12 | -$0.10 | -$0.08 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR